FDA Center for Drug Evaluation & Research Issues Warning Letter to Lovelace Biomedical Research Institute
October 14, 2026
October 14, 2026
WASHINGTON, Oct. 14 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Lovelace Biomedical Research Institute from its Center for Drug Evaluation and Research:
* * *
Recipient: Robert W. Rubin, CEO, Lovelace Biomedical Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM 87108, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
. . .
* * *
Recipient: Robert W. Rubin, CEO, Lovelace Biomedical Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM 87108, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
. . .